Bellwyck completes expansion of cold storage space in US

18 June 2019 (Last Updated June 18th, 2019 12:05)

Commercial packaging and labelling firm Bellwyck Pharma Services has completed the expansion of its cold storage space in West Chester, Ohio, US.

Commercial packaging and labelling firm Bellwyck Pharma Services has completed the expansion of its cold storage space in West Chester, Ohio, US.

The expansion includes a further 230,000ft³ of 15°C-25°C storage and will increase the company’s cold chain and controlled temperature storage and packaging capabilities at the West Chester plant.

As part of the expansion, the facility is capable of accommodating an additional 46,000ft³ of cold storage, as well as the additional space for packaging temperature-controlled pharmaceuticals.

Bellwyck Pharma Services president Greg Keizer said: “Growth in cold chain products is estimated to be twice the rate of the overall pharma market, and we have seen significant growth in the need for cold chain environments.

“Our clinical trial and commercial drug customers not only require more innovative packaging solutions that can withstand cold and frozen temperatures, but these drugs must also be consistently stored and distributed in these conditions without variation of temperature.

“Our most recent expansion will accommodate these needs and we are fortunate to be in a position of growth to keep up with the demand in the market.”

Bellwyck also added packaging services at its German facility in April 2019 to meet the global needs of its customers.

It followed a joint venture agreement signed with August Faller last year to expand its offering in Europe.

Bellwyck pharma services US operations vice-president Leah Tufts said: “Our customers trust us with storing, packaging and distributing their clinical trial materials that need refrigeration, frozen and ultra-frozen environments.

“Without the proper regulations and strict standards that we follow, the quality and efficacy of these drugs can be compromised. We know the success of their trial is in our hands and we take this very seriously which is why we continue to invest in these capabilities.”